Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics Inc's strategic decision to execute a workforce reduction demonstrates prudent financial management aimed at conserving funds during a challenging biotechnology sector environment. The company's focus on the development of promising product candidates, such as ELVN-002 and the HER3-targeting ADC, EO-1022, aligns with its commitment to driving innovation and advancing therapeutic options for patients. Additionally, the ongoing adjustments in the financial model, including the new revenue timelines and expense guidance, reflect a cautious yet optimistic approach that may enhance the company's future financial performance.

Bears say

Enliven Therapeutics Inc. faced a significant setback with the decision to discontinue the development of the Claudin 18.2-targeting ADC, EO-3021, due to lower-than-expected efficacy results in its ongoing Phase 1 study. While the drug displayed tolerability, its insufficient efficacy has made it unsuitable for further investment, raising concerns about the company's ability to attract funding or partnership opportunities for its pipeline. This development, coupled with an adjustment in the price target from $6.00 to $1.00, suggests a deteriorating outlook for Enliven Therapeutics, reflecting heightened investor skepticism concerning its future growth prospects.

ELVN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELVN has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.